Sickle Cell Biotech, Graphite Bio Prices Upsized Initial Public Offering

  • Graphite Bio Inc GRPH is set to go public on the heels of a $238 million raise less than ten months after getting started with a Series A funding of $45 million
  • Graphite is using a familiar tool to tackle genetic diseases with its CRISPR/Cas9 technology.
  • Graphite is looking to enroll 15 adults in the GPH101 Phase 1/2 trial, hoping to launch by mid-2021, with initial proof-of-concept data expected by the end of 2022.
  • According to the SEC S-1 filing, Graphite plans to spend about $90 million of its IPO funds on this Phase 1/2 trial, with another $40 million going to push through IND studies for each of their other two programs in X-linked severe combined immunodeficiency and Gaucher disease. 
  • An additional $80 million is to be earmarked for other preclinical candidates.
  • Graphite has set a launch price of $17 per share and will trade on NASDAQ under the ticker GRPH.

Posted In: BriefsBiotechNewsHealth CareFinancingOfferingsIPOsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.